Long-term antianginal and antiischemic effects of mibefradil, the novel t-type calcium channel blocker: A multicenter, double-blind, placebo- controlled, randomized comparison with sustained-release diltiazem

American Heart Journal

Volumn 134, Issue 2 I, 1997, Pages 220-228

  Davies, G J ^a   Kobrin, I ^a   Caspi, A ^a   Reisin, L H ^a   Campos de Albuquerque, D ^a   Armagnijan, D ^a   Coelho, O R ^a   Schneeweiss, A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GLYCERYL TRINITRATE; MIBEFRADIL; PLACEBO;

ADULT; AEROSOL; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERCISE TOLERANCE; FEMALE; HEADACHE; HEART MUSCLE ISCHEMIA; HEART RATE; HEART WORK; HUMAN; LEG EDEMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; SUBLINGUAL DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; TRANSVERSE TUBULAR SYSTEM; VERTIGO;

EID: 0030961133     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(97)70128-5     Document Type: Article

References (17)

1. DA. Weiner Calcium channel blockers Med Clin North Am 72 1988 83 115
2. 2 + channel blocker with potent vasodilator but weak inotropic action J Cardiovasc Pharmacol 13 1989 754 759
3. 2 + channel in cardiac tissue Eur J Pharmacol 290 1995 155 158
4. 2 + channels by 5967 Circ Res 75 1994 144 148
5. J-P Clozel W Osterdeder CH Kleinbloesem HA Welker B Schlappi R Tudor Ro 40-5697: a new nondihydropyridine calcium antagonist Cardiovasc Drug Rev 9 1991 4 17
6. HA Welker H Eggers CH Kleinbloesem K Erb K Breithaupt R Butzer Ro 40-5967: pharmacokinetics of a new calcium antagonist Eur J Clin Pharmacol 36 suppl 1989 A304
7. ALM Bakx EE van der Wall S Braun H Emanuelsson AVG Bruschke I. Kobrin Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study Am Heart J 130 1995 748 757
8. PJLM Bernink G Prager A Schelling I. Kobrin Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967) Hypertension 27 1996 426 432
9. J-P Clozel L Banken W. Osterrieder Effects of Ro 40-5697, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil J Cardiovasc Pharmacol 14 1989 713 721
10. 2 + channel blocker Ro 40-5697, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts Cardiovasc Drug Ther 4 1990 731 736
11. MF Rousseau W Hayoshida C van Eyll OM Hess CR Benedict S Ahn Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction J Am Coll Cardiol 28 1996 972 979
12. DA Weiner SS Cutter MD. Klein Efficacy and safety of sustained- release diltiazem in stable angina pectoris Am J Cardiol 57 1986 6 9
13. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med 319 1988 385 392
14. M Véniant J-P Clozel P Hess R Wolfgang Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction J Cardiol Pharmacol 17 1991 277 284
15. M Véniant J-P Clozel P Hess R Wolfgang Hemodynamic profile of Ro-40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine J Cardiovasc Pharmacol 18 Suppl 10 1991 S55 S58
16. M. Packer Pathophysiological mechanisms underlying the adverse effects of calcium channel blocking drugs in patients with chronic heart failure Circulation 80 1989 59 67
17. L Bartels W Remme A Wiesfeld A. van der Laarse High dose intravenous diltiazem increases infarct size in acute, uncomplicated myocardial infarction. A placebo-controlled study J Am Coll Cardiol 19 1992 381A